RHYTHM PHARMACEUTICALS, INC.

For the period ended Mar 31, 2026. Filed May 5, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2026 · Filed May 5, 2026

RYTM$113.94+1.5%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Balance Sheets

(in thousands, except share and per share data)

	March 31,2026	December 31,2025
Assets
Current assets:
Cash and cash equivalents	$62,137	$54,301
Short-term investments	278,488	334,648
Accounts receivable, net	34,192	26,081
Inventory	28,651	25,753
Prepaid expenses and other current assets	26,622	26,133
Total current assets	430,090	466,916
Property and equipment, net	1,065	1,104
Right-of-use asset	2,936	3,049
Intangible assets, net	5,106	5,319
Restricted cash	601	522
Other long-term assets	2,518	3,286
Total assets	$442,316	$480,196
Liabilities, Convertible Preferred Stock and Stockholders’ equity
Current liabilities:
Accounts payable	$12,299	$13,947
Accrued expenses and other current liabilities	80,045	83,855
Lease liability	676	650
Deferred revenue	48	194
Deferred royalty obligation, current	10,130	7,296
Total current liabilities	103,198	105,942
Long-term liabilities:
Deferred royalty obligation	98,339	100,886
Lease liability, non-current	3,163	3,342
Total liabilities	204,700	210,170
Commitments and contingencies (Note 14)
Series A convertible preferred stock, $0.001 par value: 150,000 shares authorized; 115,000 and 132,500 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively. Liquidation preference of $115,000 and $132,500 as of March 31, 2026, and December 31, 2025, respectively.	114,710	130,957
Stockholders’ equity:
Preferred stock, $0.001 par value: 9,850,000 shares authorized; no shares issued and outstanding at March 31, 2026 and December 31, 2025	—	—
Common stock, $0.001 par value: 120,000,000 shares authorized; 68,445,084 and 67,205,321 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively	69	67
Additional paid-in capital	1,529,909	1,491,675
Accumulated other comprehensive income (loss)	444	(796)
Accumulated deficit	(1,407,516)	(1,351,877)
Total stockholders’ equity	122,906	139,069
Total liabilities, convertible preferred stock and stockholders’ equity	$442,316	$480,196

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.